# A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers

> **NCT04104997** · PHASE1 · COMPLETED · sponsor: **GL Pharm Tech Corporation** · enrollment: 39 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** 5% GLH8NDE
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04104997
- **Lead sponsor:** GL Pharm Tech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-26
- **Primary completion:** 2020-02-18
- **Final completion:** 2020-07-17
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04104997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04104997, "A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04104997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*